Amgen Cash Flow | StatInvestor

Health Care & Life Sciences » Biotechnology | Amgen Inc.

Amgen Inc. | Cash Flow

Fiscal year is January-December. All values USD Millions.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

5,081

5,158

6,939

7,722

1,979

8,394

Depreciation, Depletion & Amortization

1,286

2,092

2,108

2,105

1,955

1,946

Other Funds

655

284

140

697

Funds from Operations

6,684

7,434

8,616

10,353

3,267

10,674

Changes in Working Capital

393

1,121

1,115

7,910

622

Net Operating Cash Flow

6,291

8,555

9,731

10,354

11,177

11,296

Capital Expenditures

693

1,003

649

837

664

Sale of Fixed Assets & Businesses

274

Purchase/Sale of Investments

2,248

4,449

4,421

7,677

3,193

Net Investing Cash Flow

8,469

5,752

5,547

8,658

4,024

Cash Dividends Paid - Total

1,415

1,851

2,396

2,998

3,365

Issuance/Reduction of Debt, Net

4,683

1,129

1,065

3,593

Net Financing Cash Flow

2,726

2,877

3,771

2,599

6,594

Net Change in Cash

548

413

903

559

Free Cash Flow

5,598

7,837

9,137

9,616

10,513

Deferred Taxes & Investment Tax Credit

189

108

607

183

1,330

363

Net Assets from Acquisitions

9,434

165

359

Change in Capital Stock

536

1,785

2,910

3,160

Other Uses

590

135

392

222

159

About Amgen

View Profile

Address	One Amgen Center Drive Thousand Oaks California 91320 United States
Employees	-
Website	http://www.amgen.com
Updated	07/08/2019
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K.